Kornimate/medical-research-clean huggingface dataset:
comparison of twice- and four-times-daily amoxicillin administration in 2-week tegoprazan-based h. pylori eradication

Conditions: H.Pylori Infection

Summary: gastric acid depressant play a major role in an h. pylori eradication therapy by (1) increasing the intragastric ph, which improves antibiotic stability and bioavailability; (2) increasing the intragastric ph to 6 or more, which prompts h. pylori to replicate and thus become more sensitive to antibiotics that are effective only against replicating bacteria, such as amoxicillin; (3) increasing the concentration of antibiotics in the stomach. of antimicrobial agents against h. pylori, amoxicillin is a penicillin derivative that inhibits the synthesis of the bacterial cell wall. therefore, amoxicillin's bactericidal effect requires the bacteria to be replicating. amoxicillin is excreted by the kidneys, the plasma half-life is approximately 1 hour, and the bactericidal effect is time dependent. theoretically, amoxicillin should be given 3 or 4 times daily to maximize the time above minimal inhibitory concentration (mic) however, in most h. pylori eradication therapies, amoxicillin is given twice daily, where the estimated time above mic attained by twice daily dosing is insufficient for amoxicillin. because most strains of h. pylori are sensitive to amoxicillin, 3 or 4 times daily administration may be appropriate to increase the h. pylori eradication success. nevertheless, data regarding the amoxicillin dosing interval for successful h. pylori eradication are lacking.

the investigators aim to compare the h. pylori eradication rates between twice- and four-times-daily amoxicillin administration in 2-week tegoprazan-based triple therapy. secondary outcomes are treatment compliance and drug-related adverse event rates.

Eligibility criteria:
inclusion criteria: * gastroscopy can be performed * h. pylori test and pathological analysis can be performed exclusion criteria: * age \ 80 years * anemia (serum hemoglobin level \< 10 g/dl) * severe systemic disease * advanced chronic liver disease * use of certain medications, including proton pump inhibitors, h2- receptor antagonists, or antibiotics * history of h. pylori eradication * drug allergy to antibiotics * history of gastric surgery * recent history of upper gastrointestinal bleeding
evaluation of in vitro devices on self-collected vaginal swab and urine sample for testing of human papilloma virus

Conditions: Cervical Intraepithelial Neoplasia Grade 2/3; Neoplasm Cervix; Carcinoma in Situ; Carcinoma Cervix Uterine; Neoplasms; Neoplasms by Histologic Type

Summary: the european valhudes study is a clinical performance /diagnostic test accuracy study that aims to evaluate whether hpv testing with new assays performed on self-samples, collected by means of a vaginal and a urine collection device is as accurate to detect cervical pre-cancer as on cliniciantaken cervical samples.

women accessing the colposcopy centres for a colposcopy examination and fulfilling the selection criteria will be asked, after written informed consent, to self-collect a first-void urine (with the colli-pee device) and a vaginal sample (with the floqswab device), prior to undergoing colposcopy. just before colposcopic examination, a clinician will also take a cervical sample (with a cervex-brush using the same procedure normally adopted for cervical cytology and/or hpv testing. during colposcopy, a colposcopy-targeted biopsy may be taken if appropriate. when according to colposcopy and biopsy results, an excisional treatment of a cervical precancer lesion is needed, the histology of the excised tissue will complete the end point of the study. the colposcopy and histological findings will be used as the gold standard if biopsies are taken. in case of normal satisfactory colposcopic findings without biopsy taking, colposcopy will provide the study outcome. three new pcr-based hpv 'in vitro diagnostic devices' (papilloplex, hpv oncopredict rna, hpv oncopredict dna) developed as part of the sme instrument project 'hpv oncopredict (ga-806551)' will be assessed.

Eligibility criteria:
inclusion criteria: * women referred to colposcopy evaluation for any reason \[i.e. previous history of abnormal cervical screen test results (cytology, hpv test), previous abnormal colposcopy\] * ability to understand and sign the informed consent * informed consent given exclusion criteria: * age \ 65 years * past history of hysterectomy * women with known pregnancy * pregnancy within last 3 months * vulnerable patient: a patient who is or may be for any reason unable to take care of him or herself, or unable to protect him or herself against significant harm or exploitation * simultaneous involvement in any other research project

Keywords: self-sampling hpv testing diagnostic test accuracy cervical intraepithelial neoplasia urine cervical cancer screening
exploring the visual sensitivity for topological properties in newborn infants

Conditions: Visual Sensitivity in Newborns

Summary: the topological perception theory proposed a precise description for how one organizes the visual world that eliminates the vagueness of subjective phenomenology. in addition, the topological theory challenges the dominant computational view on the part-to-whole hierarchy of visual information processing. lines of evidence from adult psychophysics, brain imaging data, and even honeybee's behavior have supported the notion that the global topological properties are the very primitives of visual representation. however, the question of how the sensitivity to topological properties originates during development has not been explored much. in a previous study, the investigators found that 2- to 6 month old infants could reliably discriminate stimuli based on topological differences, but failed to do so based on geometric differences. using familiarization/novelty preference procedure, the present study intends to explore the visual sensitivity for topological properties in newborn infants. experiment 1 focuses on whether neonates can discriminate a disk (no hole) and a ring (with a hole) that are topologically different, and/or a disk (no hole) and a triangle (no hole) that are geometrically different. experiment 2 focuses on whether neonates can detect a change in the number of holes and/or the size of the hole. if newborn infants are only sensitive to topological properties and not to geometric properties, this will be a strong proof for the claim that topological property is the very "primitive" visual representation at empirical as well as theoretical level.


Eligibility criteria:
inclusion criteria: * full-term and healthy newborns exclusion criteria: * eye illnesses or other physical problems

Keywords: perceptual development topological perception theory familiarization/novelty preference method discriminate a disk and a ring (topologically different), discriminate a disk and a triangle (geometrically different) detect a change in the number of holes detect the size of the hole
the response to ajmaline provocation in healthy subjects

Conditions: Brugada Syndrome; Sudden Death

Summary: standard, high lead and sodium channel provoked electrocardiograms of a healthy volunteers will be performed to observe the various ecg changes. participants will the undergo detailed imaging with cardiac magnetic resonance imaging and deep genotyping to identify structural or genetic variants which might dictate the electrocardiographic patterns at rest and with sodium channel provocation.

the investigators will recruit healthy subjects without a history of cardiac symptoms or a family history of sudden death or premature arrhythmogenic cardiac disease. participants will undergo electrocardiographic phenotype assessment with standard and high lead electrocardiogram and sodium channel provocation. detailed cardiac structural examination will be performed with cardiac magnetic resonance imaging to look for any variation in mainly right ventricular outflow tract structure and myocardial architecture. participants will also undergo targeted genomic sequencing to look for variations in genes encoding for cardiac sodium channel.

Eligibility criteria:
inclusion criteria: * asymptomatic healthy volunteers exclusion criteria: * • any prior cardiovascular illness * previous cardiac symptoms. * history of unexplained syncope * any family history of proven sudden cardiac death or unexplained sudden death either in adulthood or infancy. * those unable to provide a two generation family history * abnormal resting ecg * any contraindications to cardiac magnetic resonance imaging * pregnant or breastfeeding women * intercurrent use of any medication known to be contraindicated in brugada syndrome

Keywords: brugada syndrome scn5a scn10a ajmaline
a study of dulaglutide (ly2189265) in participants with type 2 diabetes mellitus in india

Conditions: Diabetes Mellitus, Type 2

Summary: the main purpose of this study is to evaluate safety of dulaglutide in participants with type 2 diabetes mellitus in india.


Eligibility criteria:
inclusion criteria: * have a diagnosis of type 2 diabetes mellitus (t2dm) of at least 1-year duration currently treated with stable doses of oral antihyperglycemic medications with or without stable doses of basal or premix insulin for the last 3 months prior to screening * have hemoglobin a1c (hba1c) greater than or equal to (≥) 7.5 percent (%) and less than or equal to (≤) 11.5%, both inclusive, at screening * have body mass index (bmi) ≥ 23 kilogram/square meter (kg/m²) exclusion criteria: * a diagnosis of type 1 diabetes mellitus (t1dm) or latent autoimmune diabetes, or specific type of diabetes other than t2dm * been treated with antihyperglycemic medication like glucagon-like peptide receptor agonists (glp-1 ra) or have a prior history of any contraindication to glp-1 ra therapy within 3 months prior to screening or estimated glomerular filtration rate (egfr) \<15 milliliter/minute (ml/min)/1.73 square meter (m²) * participants have known hypersensitivity or allergy to dulaglutide or its excipients * participants are on systemic steroids for any period of more than 14 days * participants have severe gastrointestinal (gi) disease, including severe gastroparesis * participants have an active or untreated malignancy, except for successfully treated basal or squamous cell carcinoma

Keywords: adult glp-1
perinatal emotion and relationships longitudinal study

Conditions: Depression, Postpartum

Summary: this study, funded by the john templeton foundation, will examine birth and the early postpartum period (bepp) as a transformative life experience that may shift women's experience of emotion in such ways as to a) support enhanced other-oriented emotions and b) underlie risk or resilience from psychopathology.

specifically, the study will investigate the extent to which women can accurately have knowledge about and predict changes in self- and other-oriented emotion processes associated with bepp. the investigators will also characterize the extent to which bepp changes self- and other-oriented emotion processes and self- and other-oriented social behaviors. further, the investigators will identify distinct trajectories of change in cognitive processes and self- and other-oriented emotion processes related to bepp, and examine how those trajectories are associated with psychological adjustment (e.g., risk and relapse of psychopathology). finally, the investigators will identify which particular features of bepp are related to distinct patterns of change in self- and other-oriented emotion processes.

Eligibility criteria:
inclusion criteria: * over age 18 * female * currently pregnant - approximately no more than 34 weeks gestational age * able to read and write in english fluently * mdd group: meet dsm-iv/dsm-5 criteria for at least 1 past episode of major depressive disorder * mdd group: do not meet dsm-iv/dsm-5 criteria for any episodes of major depressive disorder in past 2 months (currently in symptom remission) exclusion criteria: * previous birth to a living child (i.e., this pregnancy is not their first child) * imminently suicidal or homicidal * history of severe head trauma, stroke, neurological disease * history of brain tumors or surgery * severe medical illness (e.g., autoimmune disorder, blindness, cardiovascular disease, hiv/aids) * endocrine disorders (e.g., cushing's disease, thyroid disorder) * alcohol/substance abuse or dependence within the past six months * current psychotic episode (impairing ability to consent, participate, or keep patient and experimenter safe) * inability to follow study procedures * ctl group: current or lifetime axis i disorder (i.e., anxiety disorders, major depression, mania/hypomania, dysthymia, schizophrenia, schizoaffective disorder, substance abuse/dependence, eating disorders, hypochondriasis, pain disorder, or adjustment disorders)
beneficial effects of grape seed proanthocyanidin extrat on progression of atherosclerotic plaques in clinical use

Conditions: Atherosclerosis of Arteries of the Extremities, Unspecified

Summary: the purpose of this study is to investigate the antiatherogenic effect of gspe in clinical use

atherosclerotic plaques indicate the occurrence of ischemia events and how to deal with it is a difficult task for clinical physicians. grape seed proanthocyanidin extrat (gspe) has been reported to exert an antiatherogenic effect by inducing regression of atherosclerotic plaques in animal experimental studies. in this study, the antiatherogenic effect of gspe has been investigated in clinical use.

Eligibility criteria:
inclusion criteria: * (1) carotid ultrasound examination: presence of carotid plaque or abnormal cimt of between 0.9 and 1.2mm; (2) lipid profile: ldl≦3.12mmol/l, tc≦5.2mmol/l; (3) no lipid-lowering treatment within the past 6 months. exclusion criteria: * severe cardiomyopathy, acute coronary syndrome, hepatic dysfunction, end-stage renal failure (serum creatinine ≥117mmol/l), prior carotid endarterectomy, and/or patients who did not agree to participate in the present study.

Keywords: proanthocyanidin,atherosclerosis, carotid plaque
social dysfunction and brain dysfunction in patients with schizophrenia

Conditions: Schizophrenia; Social Cognition

Summary: there were a few studies about the relationship of structural or functional abnormalities of brain and social cognitive dysfunctions in patients with schizophrenia. in addition, default network, which increases activity during mental explorations referenced to oneself including remembering, considering hypothetical social interactions, and thinking about one's own future, may be associated with social cognitive dysfunctions in patients with schizophrenia. therefore, we will investigate the dysfunction of default network in patients with schizophrenia compared with healthy controls and the effect of default network dysfunctions on the social cognition in patients with schizophrenia.


Eligibility criteria:
patients group inclusion criteria: * right-handed * intelligent quotient(iq) above 80 * can read and understand the informed consent * schizophrenia patients who was diagnosed from structured clinical interview for diagnostical and statistical manual of mental disorder 4th edition(dsm-iv, nonpatient version(scid-np) scales * patient who has had reality distortion symptoms (like delusion or hallucination) in 5 years control group inclusion criteria : * right-handed * iq above 80 * do not have any diagnosis from scid-np scales * do not have any family members who have psychiatric disorder exclusion criteria: * have illness which can affect brain structures and functions * can't be taken magnetic resonance imaging(mri)
nerve stimulator versus ultrasound-guided infraclavicular block

Conditions: Pain

Summary: the investigators compared the postoperative analgesia of nerve stimulator-guided and ultrasound-guided infraclavicular block for upper extremity surgery.

ultrasound (us)-guided peripheral nerve block has increased in popularity. it has many advantages such as improved success rate, faster onset time, fewer needle passes, shorter performance time, and reduced procedural pain and vascular puncture. however, there is no information about postoperative analgesia. therefore, the investigators tested whether ultrasound-guided peripheral nerve block enhanced the postoperative analgesia for upper extremity surgery compared with nerve stimulator (ns) guidance.

Eligibility criteria:
inclusion criteria: * american society of anesthesiologists physical class i - iii patients scheduled to undergo upper extremity surgery exclusion criteria: * coagulopathy, severe pulmonary disease, neuropathy, contralateral diaphragmatic paresis, allergy to study medications

Keywords: nerve stimulator ultrasound
the effect of remimazolam on opioid induced hyperalgesia

Conditions: Hyperalgesia, Mechanical

Summary: the goal of this prospective, randomized, controlled study is to investigate the effect of remimazolam on opioid-induced hyperalgesia (oih) in patients undergoing single port-laparoscopically assisted urologic surgery. the main question\[s\] it aims to answer are: * \[the mechanical hyperalgesia threshold\] * \[area of hyperalgesia around the surgical incision 24 h after surgery (cm\^2)\] in three groups: group rhr (remimazolam- high-dose remifentanil), group dhr (desflurane-low-dose remifentanil) or group dlr (control).

ninety-three (n = 31 per group) american society of anesthesiologists i-ii patients (age 20-65 years) will be scheduled for single port-laparoscopically assisted urologic surgery. group rhr (remimazolam-remifentanil): administer remimazolam at a dose of 6 mg/kg/h initially, followed by 1 mg/kg/h, and remifentanil at 0.3 µg/kg/min. group dhr (desflurane-remifentanil): administer desflurane at 1 minimum alveolar concentration (mac), adjusting the dose by 1 vol% titration to maintain map and bis levels, and remifentanil at 0.3 µg/kg/min. group dlr (control): administer desflurane at 1 mac, adjust the dose by 1 vol% titration to maintain mean arterial pressure (map) and bispectral index (bis) levels, and remifentanil at 0.3 µg/kg/min. mechanical hyperalgesia threshold, time to first postoperative analgesic requirement (min), injected pca volume containing morphine for 12 h after surgery (ml), pain intensity: vas 1 h after surgery, vas 6 h after surgery, vas 12 h after surgery vas 24 h after surgery. area of hyperalgesia around the surgical incision 24 h after surgery (cm\^2) will be checked.

Eligibility criteria:
1. inclusion criteria will include as follows; asa(american society of anesthesiologists)physical status 1-2 patients, age with 20-65 years, and single port-laparoscopically assisted urologic surgery. 2. exclusion criteria will include as follows; a known allergy to remimazolam or remifentanil, a history of drug or alcohol abuse, psychiatric disorders, acute cardiovascular disorders, or unstable hypertension, and other respiratory or neuromuscular pathology, treated with opioid-containing any analgesic drug within 24 h before surgery and contraindications to the self-administration of opioids (i.e., were unable to understand the pca device).

Keywords: remifentanil remimazolam opioid-induced hyperalgesia
intravascular ultrasound guided drug eluting stents implantation in "all-comers" coronary lesions （ultimate trial）

Conditions: Coronary Artery Disease

Summary: a number of 1448 patients scheduled for elective percutaneous coronary intervention (pci) with a native coronary stenosis suitable for des implantation and ivus imaging are openly randomized 1:1 to either ivus guidance or angiographic guidance groups.

the study is prospectively conducted at 8 high-volume pci centers in china with ivus expertise. clinic follow-up are planned in all patients 12 months after implantation of drug eluting stents. primary endpoint is target vessel failure. the study is powered for primary endpoint, which are likely to reach significance at the level p \< 0.05 even at a follow-up drop-out rate up to 10%.

Eligibility criteria:
inclusion criteria: * provision of informed consent prior to any study specific procedures; * men and women 18 years and older;. * established indication to pci according to the guidelines of american heart association and american college of cardiology; * native coronary lesion suitable for drug-eluting stent placement and ivus imaging. exclusion criteria: * pregnancy and breast feeding mother; * co-morbidity with an estimated life expectancy of \< 50 % at 12 months; * scheduled major surgery in the next 12 months; * inability to follow the protocol and comply with follow-up requirements or any other reason that the investigator feels would place the patient at increased risk; * previous enrolment in this study or treatment with an investigational drug or device under another study protocol in the past 30 days; * known allergy against ticagrelor, or against clopidogrel, or aspirin history of major hemorrhage (intracranial, gastrointestinal, etc.); * chronic total occlusion lesion in either lad, or lcx or rca not re-canalized; * severe calcification needing rotational atherectomy； * patient with stemi (within 24-hour from the onset of chest pain to admission).

Keywords: percutaneous coronary intervention drug-eluting stent intravascular ultrasound
a study of relatlimab in combination with nivolumab in participants with advanced liver cancer who have never been treated with immuno-oncology therapy after prior treatment with tyrosine kinase inhibitors

Conditions: Hepatocellular Carcinoma; Hepatoma; Liver Cancer, Adult; Liver Cell Carcinoma; Liver Cell Carcinoma, Adult

Summary: the purpose of this study is to evaluate the effectiveness and safety of relatlimab in combination with nivolumab in participants with advanced liver cancer who have never been treated with immuno-oncology therapy, after prior treatment with tyrosine kinase inhibitor therapy.


Eligibility criteria:
key inclusion criteria: * must have a diagnosis of hepatocellular carcinoma (hcc) based on histological confirmation * must have advanced/metastatic hcc * have to be immunotherapy treatment-naive in the advanced/metastatic setting * must have at least one response evaluation criteria in solid tumors (recist) v1.1 measurable untreated lesion * child-pugh score of 5 or 6 * eastern cooperative oncology group (ecog) performance status 0 or 1 for ecog performance status scale key exclusion criteria: * known fibrolamellar hcc, sarcomatoid hcc, combined hepatocellular cholangiocarcinoma * prior organ allograft or allogeneic bone marrow transplantation * no uncontrolled or significant cardiovascular disease * no active known autoimmune disease * have received one or two lines of tyrosine kinase inhibitor therapies * evidence of radiographic progression on or after the last line of tyrosine kinase inhibitor therapy other protocol-defined inclusion/exclusion criteria apply

Keywords: hepatocellular carcinoma advanced hepatocellular carcinoma liver cancer liver cancer, adult liver cell carcinoma liver cell carcinoma, adult